Nasdaq's board diversity disclosure rule was vacated and is no longer in force
The US Court of Appeals for the Fifth Circuit vacated the SEC's approval of Nasdaq's board diversity rule in December 2024, leaving US board composition governed by investor expectation rather than by mandate.
11 December 2024
Nasdaq's rule had required listed companies to disclose board diversity statistics and to have, or explain why they did not have, diverse directors. Sitting en banc, the Fifth Circuit vacated the SEC order approving it.
California's board composition statutes had already been held unconstitutional in state litigation and are not enforced. The result is that the United States now has no mandatory board diversity requirement at either federal or major state level.
US board composition remains governed by the exchanges' independence standards — a majority independent board under NYSE 303A.01 and Nasdaq 5605(b)(1), with fully independent audit, compensation and nominating committees — and by SEC Rule 10A-3 on audit-committee independence.
What it means for a cross-border candidate
For a cross-border candidate this cuts both ways. The mandate that pushed some US boards to widen their search has gone, so a diversity-framed approach to a US board now lands with proxy advisers and large asset managers rather than with a listing rule. What has not changed is the majority-independence arithmetic across roughly 5,600 issuers, which is still the largest pool of independent seats in the world.
This paragraph is the Global ID Exchange’s own reading, not a statement by any authority named above. Everything in the body of this item is a matter of record; this is judgement.
Sources
- Alliance for Fair Board Recruitment v. SEC (5th Cir., en banc, December 2024)
- NYSE Listed Company Manual 303A.01; Nasdaq Rule 5605(b)(1)
Rules change and transitional provisions frequently apply. Verify against the primary instrument before you rely on any provision described here.
Read next: the US regime in full.
Live now in the United States
Mandates open in the markets this item bears on.
Independent Director — Audit Committee Financial Expert
United States·Healthcare & Life Sciences
Nasdaq-listed mid-cap medical technology company
The company must disclose whether its audit committee includes an audit committee financial expert under SOX s.407, and the committee must be entirely independent under SEC Rule 10A-3. International expansion has also outrun the board's experience of the markets it now sells into.
Interim Chief Information Security Officer
United States·Financial Services & Fintech
US-listed financial technology company
The CISO has departed while the company is building the governance and disclosure process required by the SEC's cyber-security incident and risk-management disclosure rules. The audit committee requires continuity of accountability.
Related items
The whole feedThe EU's board gender-balance deadline has passed, and it binds every large listed company in the Union
Directive (EU) 2022/2381 required listed companies to meet its board gender-balance objective by 30 June 2026. The obligation is now live across every member state.
Read the full itemThe UK board's declaration on internal controls starts biting for financial years beginning in 2026
Provision 29 of the UK Corporate Governance Code 2024 requires the board to declare the effectiveness of its material controls — financial, operational, reporting and compliance.
Read the full itemHong Kong put a nine-year clock on every independent non-executive seat
HKEX's Corporate Governance Code amendments took effect on 1 July 2025, introducing a hard nine-year cap on INED independence with a phased transition running to 2028.
Read the full item